- Home
- BIVI vs XAIR Comparison
BIVI vs XAIR Comparison
Compare BIVI & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- XAIR
- Stock Information
- Founded
- BIVI 2013
- XAIR 2011
- Country
- BIVI United States
- XAIR United States
- Employees
- BIVI N/A
- XAIR N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- BIVI Health Care
- XAIR Health Care
- Exchange
- BIVI Nasdaq
- XAIR Nasdaq
- Market Cap
- BIVI 15.0M
- XAIR 17.0M
- IPO Year
- BIVI N/A
- XAIR N/A
- Fundamental
- Price
- BIVI $6.03
- XAIR $2.86
- Analyst Decision
- BIVI
- XAIR Strong Buy
- Analyst Count
- BIVI 0
- XAIR 3
- Target Price
- BIVI N/A
- XAIR $23.67
- AVG Volume (30 Days)
- BIVI 66.5K
- XAIR 387.2K
- Earning Date
- BIVI 09-29-2025
- XAIR 08-12-2025
- Dividend Yield
- BIVI N/A
- XAIR N/A
- EPS Growth
- BIVI N/A
- XAIR N/A
- EPS
- BIVI N/A
- XAIR N/A
- Revenue
- BIVI N/A
- XAIR $3,705,000.00
- Revenue This Year
- BIVI N/A
- XAIR $266.61
- Revenue Next Year
- BIVI N/A
- XAIR $140.76
- P/E Ratio
- BIVI N/A
- XAIR N/A
- Revenue Growth
- BIVI N/A
- XAIR 219.67
- 52 Week Low
- BIVI $5.74
- XAIR $2.75
- 52 Week High
- BIVI $75.00
- XAIR $13.52
- Technical
- Relative Strength Index (RSI)
- BIVI 34.02
- XAIR 37.13
- Support Level
- BIVI $7.24
- XAIR $2.93
- Resistance Level
- BIVI $7.75
- XAIR $3.78
- Average True Range (ATR)
- BIVI 0.72
- XAIR 0.26
- MACD
- BIVI -0.10
- XAIR -0.03
- Stochastic Oscillator
- BIVI 8.78
- XAIR 8.91
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.